Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Buprenorphine
Sixmo
Not routinely available
SMC (SMC2372)
02/02/2022
Indication
Substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
Therapeutic Area
Central nervous system
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
74.2mg implant